8-KLeadership Changes

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (Oct 5, 2023)

Filed October 5, 2023For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. (VRTX) announced a significant change to its board of directors with the appointment of Michel Lagarde, effective October 5, 2023. Mr. Lagarde brings extensive experience from leadership roles at Thermo Fisher Scientific, including his current position as Executive Vice President and Chief Operating Officer. His background also includes experience in private equity within the healthcare sector, suggesting a valuable addition to Vertex's strategic oversight. This appointment increases the size of the Board from nine to ten members. Mr. Lagarde's compensation for joining the board includes a substantial $400,000 restricted stock unit award, which is scheduled to vest in October 2024. This signals a commitment to aligning director interests with shareholder value. The filing also confirms no related-party transactions or specific appointment understandings requiring further disclosure.

Key Highlights

  • 1Michel Lagarde appointed as a new member of the Board of Directors, effective October 5, 2023.
  • 2Board size increased from nine to ten members.
  • 3Mr. Lagarde's extensive experience includes his current role as Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific.
  • 4His prior roles at Thermo Fisher and Patheon N.V., along with his background in private equity (JLL Partners), provide valuable industry and financial expertise.
  • 5Mr. Lagarde received a $400,000 restricted stock unit award upon appointment, vesting in October 2024.
  • 6No reportable transactions between the Company and Mr. Lagarde under Item 404(a) of Regulation S-K.
  • 7No arrangements or understandings exist for Mr. Lagarde's appointment beyond standard board procedures.

Frequently Asked Questions

Michel Lagarde has been appointed as a new member of Vertex's Board of Directors. He brings significant operational and executive leadership experience, currently serving as Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific, a major player in the life sciences and pharmaceutical services industry. His background is expected to contribute valuable strategic insights and operational expertise to Vertex's governance.

Mr. Lagarde's appointment has increased the size of the Board of Directors from nine to ten members. This expansion may indicate a strategic move by Vertex to bring in specialized expertise or to accommodate growth and evolving company needs.

Upon joining the Board, Mr. Lagarde received a restricted stock unit award valued at $400,000. This award is subject to a vesting period and is expected to vest in October 2024, aligning his incentives with the long-term performance of Vertex's stock.

The filing explicitly states that there are no transactions involving Vertex Pharmaceuticals and Mr. Lagarde that are required to be reported under Item 404(a) of Regulation S-K, and no special arrangements or understandings exist for his appointment. This suggests a clean integration onto the board from a disclosure perspective.